4 result(s) for
|PI Name||Protocol #||Title|
|Zahi Mitri||IRB00006256||I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2|
|Zahi Mitri||STUDY00018504||A Phase II, Open Label, Study of Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer|
|Charles Lopez||STUDY00019211||A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients with Pancreatic Ductal Adenocarcinoma|
|Adel Kardosh||STUDY00021972||A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)|
You may also qualify for Phase 1 Program trials.
For more information: